Skip to main content
Premium Trial:

Request an Annual Quote

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

NEW YORK ─ Vela Diagnostics said on Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for its ViroKey SARS-CoV-2 RT-PCR Test v2.0.

The automated probe-based RT-PCR test detects SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs and is optimized for a workflow consisting of Vela Diagnostics' Sentosa SX101 and Sentosa SA201 instruments. The test enables high-throughput testing of up to 46 samples in a single run with reduced hands-on time, Vela said.

In August, the Singapore-based company received FDA EUA for a manual version of the ViroKey SARS-CoV-2 RT-PCR Test.

Rachel Yap, product manager at Vela, said in an email that the new test is multiplexed, targeting the virus' ORF1a and N genes, and has a better limit of detection than the manual version, in addition to providing automated analysis and reporting of results.

The firm said it has also received provisional authorization for use of the test from the Singapore Health Sciences Authority.

In July, Vela announced it had received CE marking for the automated test. In April, it received CE marking for the nonautomated version.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.